Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Interferon alpha/beta

Group I interferon including pegylated IFN

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)
I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g

Pulmonary fibrosis
I.n

ILD with a granulomatous component
I.w

Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence
I.z

Progression, acceleration or exacerbation of preexisting ILD/fibrosis

XLI - Pulmonary edema - Acute lung injury - ARDS

XLI.a

Pulmonary edema, noncardiogenic (NCPE)
XLI.e

ARDS - Acute lung injury

XLIII - Airway involvement

XLIII.a

Bronchospasm - Wheezing - Asthma
XLIII.r

Plugs/casts in the airways
XLIII.ab

Cough (lone)

XLIV - Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a

Angioedema (may cause UAO, asphyxia and death)

XLV - Pleural and/or pericardial involvement

XLV.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLVI - Pulmonary vasculopathy

XLVI.b

Pulmonary arterial hypertension
XLVI.d

Pulmonary vasculitis or capillaritis
XLVI.f

Hemolytic and uremic syndrome (HUS). See also under Xaf

XLVII - Mediastinal involvement

XLVII.a

Lymphadenopathy (intrathoracic)
XLVII.e

Granulomatous mediastinal lymphadenopathy

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.b

Antiphospholipid antibodies w/wo the APL syndrome
XLIX.c

Capillary leak syndrome (CLS)
XLIX.d

Lupus - Lupus syndrome (see also Vd)
XLIX.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)
XLIX.l

Myopathy-Myositis-Polymyositis (see also under Xba)
XLIX.m

Sarcoid-like granulomatosis (endo-/extrathoracic)
XLIX.w

Multiple organ dysfunction/failure (MODS/MOF)

L - Miscellaneous

L.l

Neutropenia, agranulocytosis (w/wo infection/sepsis)

LVIII - Pathology

LVIII.a

Path: NSIP-cellular pattern (see also Ia, Ib)
LVIII.d

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
LVIII.f

Path: ILD with a granulomatous component (see also Im)
LVIII.k

Path: Desquamative interstitial pneumonia (DIP-pattern)
LVIII.o

Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LIX - Infections & related conditions

LIX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo